Literature DB >> 6385883

Inhibition of prostaglandin synthesis restores normal hemodynamics in canine hyperdynamic sepsis.

M P Fink, T J MacVittie, L C Casey.   

Abstract

This study investigates the role of prostaglandins (PG) in hyperdynamic sepsis. Thirteen chronically instrumented dogs were rendered septic by implanting in the peritoneal cavity a fibrin clot containing viable Escherichia coli. One day later, cardiac output (CO) increased from 2.80 +/- 0.22 to 3.72 +/- 0.32 l/min (p = 0.011); heart rate (HR) increased from 122 +/- 8 to 147 +/- 6 beats/min (p = 0.005); mean pulmonary artery pressure (PAP) increased from 15 +/- 1 to 19 +/- 1 mmHg (p = 0.003); mean systemic arterial pressure (MAP) decreased from 120 +/- 5 to 107 +/- 7 mmHg; and systemic vascular resistance (SVR) decreased from 44.1 +/- 2.6 to 29.3 +/- 1.9 mmHg/l/min (p less than 0.001). Sixty minutes after intravenous injection of indomethacin (2 mg/kg) or ibuprofen (25 mg/kg), CO decreased to 2.60 +/- 0.21 l/min (p less than 0.001); HR decreased to 118 +/- 5 beats/min (p less than 0.001); PAP decreased to 17 +/- 1 mmHg (p = 0.021); and SVR increased to 43.7 mmHg/l/min (p less than 0.001). In seven control dogs, laparotomy alone did not significantly affect any of these parameters. Infusion of indomethacin caused a slight increase in MAP (106 +/- 4 to 116 +/- 4 mmHg, p = 0.035) but otherwise did not alter hemodynamics. It is concluded that administration of indomethacin or ibuprofen restores normal hemodynamics in a canine model of high-output sepsis, probably by inhibiting PG synthesis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6385883      PMCID: PMC1250546          DOI: 10.1097/00000658-198411000-00011

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  32 in total

1.  Prostaglandin F and E levels during endotoxin-induced pulmonary hypertension in calves.

Authors:  F L Anderson; T J Tsagaris; W Jubiz; H Kuida
Journal:  Am J Physiol       Date:  1975-05

2.  Capillary muscle blood flow in human sepsis.

Authors:  R J Finley; J H Duff; R L Holliday; D Jones; J B Marchuk
Journal:  Surgery       Date:  1975-07       Impact factor: 3.982

3.  Differential inhibition by prostaglandins of the renal actions of pressor stimuli.

Authors:  A J Lonigro; N A Terragno; K U Malik; J C McGiff
Journal:  Prostaglandins       Date:  1973-05

4.  Studies on the effect of prostaglandins E1 and E2 on the sympathetic neuromuscular transmission in some animal tissues.

Authors:  P Hedqvist
Journal:  Acta Physiol Scand Suppl       Date:  1970

5.  Hemodynamic and metabolic studies on shock associated with gram negative bacteremia.

Authors:  H Nishijima; M H Weil; H Shubin; J Cavanilles
Journal:  Medicine (Baltimore)       Date:  1973-07       Impact factor: 1.889

6.  Energy metabolism in sepsis: treatment based on different patterns in shock and high output stage.

Authors:  G H Clowes; T F O'Donnell; N T Ryan; G L Blackburn
Journal:  Ann Surg       Date:  1974-05       Impact factor: 12.969

7.  Plasma catecholamines in patients with serious postoperative infection.

Authors:  A C Groves; J Griffiths; F Leung; R N Meek
Journal:  Ann Surg       Date:  1973-07       Impact factor: 12.969

8.  Arteriovenous shunting in high cardiac output shcok syndromes.

Authors:  J D Cohn; M Greenspan; C R Goldstein; A L Gudwin; J H Siegel; L R DelGuercio
Journal:  Surg Gynecol Obstet       Date:  1968-08

9.  A nomogram relating pO2, pH, temperature, and hemoglobin saturation in the dog.

Authors:  R G Rossing; S M Cain
Journal:  J Appl Physiol       Date:  1966-01       Impact factor: 3.531

10.  Endotoxin-induced prostaglandin E and F release in dogs.

Authors:  F L Anderson; W Jubiz; T J Tsagaris; H Kuida
Journal:  Am J Physiol       Date:  1975-02
View more
  14 in total

Review 1.  Differential Paradigms in Animal Models of Sepsis.

Authors:  S Manoj Kumar Kingsley; B Vishnu Bhat
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

Review 2.  Scientific and clinical challenges in sepsis.

Authors:  Luis Ulloa; Michael Brunner; Laura Ramos; Edwin A Deitch
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 3.  Corticosteroids, nonsteroidal anti-inflammatory drugs, and naloxone in the sepsis syndrome.

Authors:  W M Long; C L Sprung
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

Review 4.  Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock.

Authors:  H A Ball; J A Cook; W C Wise; P V Halushka
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

Review 5.  Bacteria, toxins, and the peritoneum.

Authors:  T Hau
Journal:  World J Surg       Date:  1990 Mar-Apr       Impact factor: 3.352

6.  Establishment of a sepsis model following implantation of Klebsiella pneumoniae-infected fibrin clot into the peritoneal cavity of mice.

Authors:  V Toky; S Sharma; B B Arora; S Chhibber
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

7.  Reduced production of creatinine limits its use as marker of kidney injury in sepsis.

Authors:  Kent Doi; Peter S T Yuen; Christoph Eisner; Xuzhen Hu; Asada Leelahavanichkul; Jürgen Schnermann; Robert A Star
Journal:  J Am Soc Nephrol       Date:  2009-04-23       Impact factor: 10.121

8.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

Authors:  S Okusawa; J A Gelfand; T Ikejima; R J Connolly; C A Dinarello
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

Review 9.  Animal models of sepsis and sepsis-induced kidney injury.

Authors:  Kent Doi; Asada Leelahavanichkul; Peter S T Yuen; Robert A Star
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

10.  Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock.

Authors:  C Natanson; M P Fink; H K Ballantyne; T J MacVittie; J J Conklin; J E Parrillo
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.